We evaluated renal function in 107 patients with active lupus nephritis who participated in long-term randomized therapeutic trials (median follow-up, seven years). For patients taking oral prednisone alone, the probability of renal failure began to increase substantially after five years of observation. Renal function was better preserved in patients who received various cytotoxic-drug therapies, but the difference was statistically significant only for intravenous cyclophosphamide plus low-dose prednisone as compared with high-dose prednisone alone (P = 0.027). The advantage of treatment with intravenous cyclophosphamide over oral prednisone alone was particularly apparent in the high-risk subgroup of patients who had chronic histologic changes on renal biopsy at study entry. Patients treated with intravenous cyclophosphamide have not experienced hemorrhagic cystitis, cancer, or a disproportionate number of major infections. We conclude that, as compared with high-dose oral prednisone alone, treatment of lupus glomerulonephritis with intravenous cyclophosphamide reduces the risk of end-stage renal failure with few serious complications.
This article has been cited by other articles:
McKinley, A., Park, E., Spetie, D., Hackshaw, K. V., Nagaraja, S., Hebert, L. A., Rovin, B. H.
(2009). Oral Cyclophosphamide for Lupus Glomerulonephritis: An Underused Therapeutic Option. CJASN
4: 1754-1760
[Abstract][Full Text]
Chen, T., Ding, X., Chen, B.
(2009). Value of the RIFLE classification for acute kidney injury in diffuse proliferative lupus nephritis. Nephrol Dial Transplant
24: 3115-3120
[Abstract][Full Text]
Hobbs, D. J., Barletta, G.-M., Rajpal, J. S., Rajpal, M. N., Weismantel, D. P., Birmingham, J. D., Bunchman, T. E.
(2009). Severe paediatric systemic lupus erythematosus nephritis--a single centre experience. Nephrol Dial Transplant
0: gfp481v1-gfp481
[Abstract][Full Text]
D'Cruz, D., Houssiau, F.
(2009). The Euro-Lupus Nephritis Trial: the development of the sequential treatment protocol. Lupus
18: 875-877
[Abstract]
Berden, J. H. M.
(2009). Azathioprine, the Cinderella in the treatment of lupus nephritis. Nephrol Dial Transplant
24: 2611-2612
[Full Text]
Li, E. K., Tam, L.-S., Zhu, T. Y., Li, M., Kwok, C. L., Li, T. K., Leung, Y. Y., Wong, K. C., Szeto, C. C.
(2009). Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. Rheumatology (Oxford)
48: 892-898
[Abstract][Full Text]
Mak, A., Cheak, A. A. C., Tan, J. Y. S., Su, H. C., Ho, R. C. M., Lau, C. S.
(2009). Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford)
48: 944-952
[Abstract][Full Text]
Galindo, M., Gonzalo, E., Martinez-Vidal, M. P., Montes, S., Redondo, N., Santiago, B., Loza, E., Pablos, J. L.
(2009). Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti-phospholipid antibodies. Rheumatology (Oxford)
48: 1003-1007
[Abstract][Full Text]
Kimura, H., Li, X., Torii, K., Okada, T., Kamiyama, K., Mikami, D., Takahashi, N., Yoshida, H.
(2009). Dexamethasone enhances basal and TNF-{alpha}-stimulated production of PAI-1 via the glucocorticoid receptor regardless of 11{beta}-hydroxysteroid dehydrogenase 2 status in human proximal renal tubular cells. Nephrol Dial Transplant
24: 1759-1765
[Abstract][Full Text]
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sanchez-Guerrero, J., Solomons, N., Wofsy, D., the Aspreva Lupus Management Study Group,
(2009). Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. J. Am. Soc. Nephrol.
20: 1103-1112
[Abstract][Full Text]
RIVERA, T. L., BELMONT, H. M., MALANI, S., LATORRE, M., BENTON, L., WEISSTUCH, J., BARISONI, L., TSENG, C.-E, IZMIRLY, P. M., BUYON, J. P., ASKANASE, A. D.
(2009). Current Therapies for Lupus Nephritis in an Ethnically Heterogeneous Cohort. The Journal of Rheumatology
36: 298-305
[Abstract][Full Text]
Bargman, J. M.
(2009). How did cyclophosphamide become the drug of choice for lupus nephritis?. Nephrol Dial Transplant
24: 381-384
[Full Text]
Szeto, C.-C., Kwan, B. C.-H., Lai, F. M.-M., Tam, L.-S., Li, E. K.-M., Chow, K.-M., Gang, W., Li, P. K.-T.
(2008). Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford)
47: 1678-1681
[Abstract][Full Text]
Elizur, S. E., Chian, R. C., Pineau, C. A., Son, W. Y., Holzer, H. E. G., Huang, J. Y. J., Gidoni, Y., Levin, D., Demirtas, E., Tan, S. L.
(2008). Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology (Oxford)
47: 1506-1509
[Abstract][Full Text]
Zhu, J., Qiu, Y., Wang, Q., Zhu, Y., Hu, S., Zheng, L., Wang, L., Zhang, Y.
(2008). Low dose cyclophosphamide rescues myocardial function from ischemia-reperfusion in rats. Eur. J. Cardiothorac. Surg.
34: 661-666
[Abstract][Full Text]
Traitanon, O, Avihingsanon, Y, Kittikovit, V, Townamchai, N, Kanjanabuch, T, Praditpornsilpa, K, Wongchinasri, J, Tungsanga, K, Eiam-Ong, S
(2008). Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus
17: 744-751
[Abstract]
Houssiau, F., Ginzler, E.
(2008). Current treatment of lupus nephritis. Lupus
17: 426-430
[Abstract]
Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T
(2008). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis
67: 195-205
[Abstract][Full Text]
Bernatsky, S, Joseph, L, Boivin, J-F, Gordon, C, Urowitz, M, Gladman, D, Fortin, P R, Ginzler, E, Bae, S-C, Barr, S, Edworthy, S, Isenberg, D, Rahman, A, Petri, M, Alarcon, G S, Aranow, C, Dooley, M-A, Rajan, R, Senecal, J-L, Zummer, M, Manzi, S, Ramsey-Goldman, R, Clarke, A E
(2008). The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis
67: 74-79
[Abstract][Full Text]
Sinclair, A., Appel, G., Dooley, M.A., Ginzler, E., Isenberg, D., Jayne, D., Wofsy, D., Solomons, N.
(2007). Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus
16: 972-980
[Abstract]
Wells, A. U., Latsi, P., McCune, W. J.
(2007). Daily Cyclophosphamide for Scleroderma: Are Patients with the Most to Gain Underrepresented in this Trial?. Am. J. Respir. Crit. Care Med.
176: 952-953
[Full Text]
de Castro, W.P., Morales, J.V., Wagner, M.B., Graudenz, M., Edelweiss, M.I., Goncalves, L.F.
(2007). Hypertension and Afro-descendant ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide?. Lupus
16: 724-730
[Abstract]
Contreras, G., Sosnov, J.
(2007). Role of Mycophenolate Mofetil in the Treatment of Lupus Nephritis. CJASN
2: 879-882
[Full Text]
Ranchin, B., Fargue, S.
(2007). Review: New treatment strategies for proliferative lupus nephritis: keep children in mind!. Lupus
16: 684-691
[Abstract]
Zhu, B., Chen, N., Lin, Y., Ren, H., Zhang, W., Wang, W., Pan, X., Yu, H.
(2007). Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant
22: 1933-1942
[Abstract][Full Text]
Illei, G. G., Yarboro, C. H., Kuroiwa, T., Schlimgen, R., Austin, H. A., Tisdale, J. F., Chitkara, P., Fleisher, T., Klippel, J. H., Balow, J. E., Boumpas, D. T.
(2007). Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis. Rheumatology (Oxford)
46: 952-956
[Abstract][Full Text]
Houssiau, F
(2007). Thirty years of cyclophosphamide: assessing the evidence. Lupus
16: 212-216
[Abstract]
Haubitz, M
(2007). Exploring new territory: the move towards individualised treatment. Lupus
16: 227-231
[Abstract]
Alperovich, G, Rama, I, Lloberas, N, Franquesa, M, Poveda, R, Goma, M, Herrero-Fresneda, I, Cruzado, J M, Bolanos, N, Carrera, M, Grinyo, J M, Torras, J
(2007). New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus
16: 18-24
[Abstract]
Tse, K C, Lam, M F, Tang, S C., Tang, C S., Chan, T M
(2007). A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus
16: 46-51
[Abstract]
Yamasaki, Y., Yamada, H., Yamasaki, M., Ohkubo, M., Azuma, K., Matsuoka, S., Kurihara, Y., Osada, H., Satoh, M., Ozaki, S.
(2007). Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford)
46: 124-130
[Abstract][Full Text]
Pineau, C A, Bernatsky, S, Abrahamowicz, M, Neville, C, Karp, I, Clarke, A E
(2006). A comparison of damage accrual across different calendar periods in systemic lupus erythematosus patients. Lupus
15: 590-594
[Abstract]
Trojano, M., Russo, P., Fuiani, A., Paolicelli, D., Di Monte, E., Granieri, E., Rosati, G., Savettieri, G., Comi, G., Livrea, P., MSDN Study Group,
(2006). The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFN{beta} exposure in multiple sclerosis. Mult Scler
12: 578-585
[Abstract]
Moroni, G., Doria, A., Mosca, M., Alberighi, O. D. C., Ferraccioli, G., Todesco, S., Manno, C., Altieri, P., Ferrara, R., Greco, S., Ponticelli, C.
(2006). A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years. CJASN
1: 925-932
[Abstract][Full Text]
Baca, V, Catalan, T, Villasis-Keever, M, Ramon, G, Morales, A., Rodriguez-Leyva, F
(2006). Effect of Low-Dose Cyclosporine A in the Treatment of Refractory Proteinuria in Childhood-Onset Lupus Nephritis. Lupus
15: 490-495
[Abstract]
Ponticelli, C.
(2006). New Therapies for Lupus Nephritis. CJASN
1: 863-868
[Full Text]
Tse, K C, Tang, C S., Lio, W I, Lam, M F, Chan, T M
(2006). Quality of life comparison between corticosteroidand-mycofenolate mofetil and corticosteroidand-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus
15: 371-379
[Abstract]
Dooley, M A
(2006). Mycophenylate mofetil: what role in the treatment of lupus?. Lupus
15: 179-182
[Abstract]
Burt, R. K., Traynor, A., Statkute, L., Barr, W. G., Rosa, R., Schroeder, J., Verda, L., Krosnjar, N., Quigley, K., Yaung, K., Villa, BS, M., Takahashi, M., Jovanovic, B., Oyama, Y.
(2006). Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus. JAMA
295: 527-535
[Abstract][Full Text]
Tse, K C, Li, F K, Tang, S, Tang, C S-O, Lai, K N, Chan, T M
(2005). Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus
14: 947-952
[Abstract]
Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., Appel, G. B.
(2005). Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis.. NEJM
353: 2219-2228
[Abstract][Full Text]
Stummvoll, G H, Aringer, M, Smolen, J S, Schmaldienst, S, Jimenez-Boj, E, Horl, W H, Graninger, W B, Derfler, K
(2005). IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis
64: 1015-1021
[Abstract][Full Text]
Fine, D. M.
(2005). Pharmacological Therapy of Lupus Nephritis. JAMA
293: 3053-3060
[Abstract][Full Text]
Illei, G G
(2005). On the road to the optimal treatment of lupus nephritis: are we there yet?. Lupus
14: 263-264
Chan, T M, Tse, K C, Tang, C S., Lai, K N, Li, F K
(2005). Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus
14: 265-272
[Abstract]
Chan, T.-M., Tse, K.-C., Tang, C. S.-O., Mok, M.-Y., Li, F.-K., for the Hong Kong Nephrology Study Group,
(2005). Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis. J. Am. Soc. Nephrol.
16: 1076-1084
[Abstract][Full Text]
Chan, T M
(2005). Lupus nephritis: induction therapy. Lupus
14: s27-s32
[Abstract]
Contreras, G, Tozman, E, Nahar, N., Metz, D.
(2005). Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus
14: s33-s38
[Abstract]
Gorman, C., Bhatia, A., Rahman, A.
(2005). This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis. Rheumatology (Oxford)
44: 398-401
[Full Text]
Houssiau, F A
(2005). Cyclophosphamide in lupus nephritis. Lupus
14: 53-58
[Abstract]
Austin, H A, Illei, G G
(2005). Membranous lupus nephritis. Lupus
14: 65-71
[Abstract]
Contreras, G., Tozman, E., Nahar, N., Metz, D.
(2005). Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus
14: s33-s38
[Abstract]
Houssiau, F. A.
(2004). Management of Lupus Nephritis: An Update. J. Am. Soc. Nephrol.
15: 2694-2704
[Full Text]
Katsifis, G E, Tzioufas, A G
(2004). Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus
13: 673-678
[Abstract]
Ahmadi-Simab, K, Lamprecht, P, Gross, W L
(2004). Progression of lupus nephritis during treatment with mycophenolate mofetil. Ann Rheum Dis
63: 1179-1180
[Full Text]
Vasoo, S
(2004). First international meeting on mycophenolate mofetil: an advance in the treatment of lupus 27 April 2004, St Thomas' Hospital, London, UK. Lupus
13: 543-545
Sidiropoulos, P I, Boumpas, D T
(2004). Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus
13: 391-397
[Abstract]
Yee, C-S, Gordon, C, Dostal, C, Petera, P, Dadoniene, J, Griffiths, B, Rozman, B, Isenberg, D A, Sturfelt, G, Nived, O, Turney, J H, Venalis, A, Adu, D, Smolen, J S, Emery, P
(2004). EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis
63: 525-529
[Abstract][Full Text]
Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., Roth, D.
(2004). Sequential Therapies for Proliferative Lupus Nephritis. NEJM
350: 971-980
[Abstract][Full Text]
Balow, J. E., Austin, H. A. III
(2004). Maintenance Therapy for Lupus Nephritis -- Something Old, Something New. NEJM
350: 1044-1046
[Full Text]
Karim, Y, D'Cruz, D P
(2004). The NIH pulse cyclophosphamide regime: the end of an era?. Lupus
13: 1-3
Donia, A. F., Gazareen, S. H., Ahmed, H. A., Moustafa, F. E., Shoeib, A. A., Ismail, A. M., Khamis, S., Sobh, M. A.
(2003). Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children. Nephrol Dial Transplant
18: 2054-2058
[Abstract][Full Text]
Bhattacharya, A., Lawrence, R. A., Krishnan, A., Zaman, K., Sun, D., Fernandes, G.
(2003). Effect of Dietary n-3 and n-6 Oils with and without Food Restriction on Activity of Antioxidant Enzymes and Lipid Peroxidation in Livers of Cyclophosphamide Treated Autoimmune-Prone NZB/W Female Mice. J. Am. Coll. Nutr.
22: 388-399
[Abstract][Full Text]
Mok, C C, Lau, C S
(2003). Lupus in Hong Kong Chinese. Lupus
12: 717-722
[Abstract]
Mavragani, C P, Moutsopoulos, H M
(2003). Lupus nephritis: current issues. Ann Rheum Dis
62: 795-798
[Full Text]
Mok, C C, Wong, R W S, Lai, K N
(2003). Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis
62: 799-804
[Abstract][Full Text]
Williams, W, Bhagwandass, A, Sargeant, L A, Shah, D
(2003). Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients. Lupus
12: 640-645
[Abstract]
Cortes-Herandez, J, Ordi-Ros, J, Labrador, M, Segarra, A, Tovar, J L, Balada, E, Vilardell-Tarres, M
(2003). Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus
12: 287-296
[Abstract]
Nachman, P. H., Martin, J.
(2002). Developments in the Immunotherapy of Glomerular Disease. Journal of Pharmacy Practice
15: 472-489
[Abstract]
Illei, G. G., Balow, J. E., Boumpas, D. T.
(2002). Long-Term Outcome in Lupus Nephritis. ANN INTERN MED
137: 545-546
[Full Text]
MacGowan, J. R., Ellis, S., Griffiths, M., Isenberg, D. A.
(2002). Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology (Oxford)
41: 981-987
[Abstract][Full Text]
Karim, M. Y., Alba, P., Cuadrado, M.-J., Abbs, I. C., D'Cruz, D. P., Khamashta, M. A., Hughes, G. R. V.
(2002). Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford)
41: 876-882
[Abstract][Full Text]
Gladstone, D E, Prestrud, A A, Pradhan, A, Styler, M J, Topolsky, D L, Crilley, P A, Hoch, S, Huppert, A, Brodsky, I
(2002). High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus
11: 405-410
[Abstract]
Katsifis, G. E., Tzioufas, A. G., Vlachoyiannopoulos, P. G., Voulgarelis, M., Moutsopoulos, H. M., Ioannidis, J. P. A.
(2002). Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology (Oxford)
41: 780-786
[Abstract][Full Text]
Houssiau, F. A., Jadoul, M.
(2002). Cytotoxic therapy of lupus nephritis: recent developments. Nephrol Dial Transplant
17: 955-957
[Full Text]
Pasoto, S G, Mendonca, B B, Bonfa, E
(2002). Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus
11: 175-180
[Abstract]
Gulati, S., Pokhariyal, S., Sharma, R. K., Elhence, R., Kher, V., Pandey, C. M., Gupta, A.
(2001). Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome. Nephrol Dial Transplant
16: 2013-2017
[Abstract][Full Text]
Kingdon, E J, McLean, A G, Psimenou, E, Davenport, A, Powis, S H, Sweny, P, Burns, A
(2001). The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus
10: 606-611
[Abstract]
Illei, G. G., Austin, H. A. III, Crane, M., Collins, L., Gourley, M. F., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Steinberg, A. D., Klippel, J. H., Balow, J. E., Boumpas, D. T.
(2001). Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis. ANN INTERN MED
135: 248-257
[Abstract][Full Text]
Adu, D.
(2001). The evidence base for the treatment of lupus nephritis in the new millennium. Nephrol Dial Transplant
16: 1536-1538
[Full Text]
Lai, N-S, Lin, R-H, Lai, R-S, Kun, U-C, Leu, S-C
(2001). Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1 mice with an ancient Chinese herb, Ganoderma tsugae. Lupus
10: 461-465
[Abstract]
Zonana-Nacach, A, Camargo-Coronel, A, Yanez, P, Sanchez, L, Jimenez-Balderas, F J, Fraga, A
(2001). Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus
10: 505-510
[Abstract]
Moroni, G., Greloni, G. C., Ponticelli, C.
(2001). Late recurrence of lupus nephritis after long-term clinical remission. Nephrol Dial Transplant
16: 849-852
[Full Text]
Mosca, M, Neri, R, Giannessi, S, Pasquariello, A, Puccini, R, Bencivelli, W, Bombardieri, S
(2001). Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis. Lupus
10: 253-257
[Abstract]
Takada, K, Illei, G G, Boumpas, D T
(2001). Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus
10: 154-161
[Abstract]
Adu, D, Cross, J, Jayne, D R.
(2001). Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus
10: 203-208
[Abstract]
Daikh, D. I., Wofsy, D.
(2001). Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide. J. Immunol.
166: 2913-2916
[Abstract][Full Text]
Isenberg, D. A., Karassa, F. B., Chan, T. M., The Hong Kong-Guangzhou Nephrology Study Group,
(2001). Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis. NEJM
344: 382-383
[Full Text]
Previous
